Tag: Acousia Therapeutics GmbH

Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity

TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss,...

Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity

TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsAcousia Therapeutics GmbH

AIFA 就涉及 HyalRoute Communication Group Limited 的股份收購交易正式作出澄清及反駁

SpaceX perpetual futures become Binance’s No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues

AESC and Prevalon Energy Sign 10+ GWh Strategic Supply Agreement to Support Global Energy Storage Growth

Tag: Acousia Therapeutics GmbH

Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity

Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us